Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKesson
Boehringer Ingelheim
McKinsey
Moodys

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06463922

See Plans and Pricing

« Back to Dashboard

Drug Development Status for PF-06463922: Patents, clinical trial progress, indications

PF-06463922 is an investigational drug.

There have been 12 clinical trials for PF-06463922. The most recent clinical trial was a Phase 1 trial, which was initiated on April 7th 2017.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma, Large-Cell, Anaplastic. The leading clinical trial sponsors are Pfizer, Clinical Research Technology S.r.l., and National Cancer Institute (NCI).

There are nine US patents protecting this investigational drug and one hundred and thirty-two international patents.

Recent Clinical Trials for PF-06463922
TitleSponsorPhase
A Study of Lorlatinib in ALK Inhibitor‑Treated ALK‑Positive NSCLC in ChinaPfizerPhase 2
Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol)National Cancer Institute (NCI)Phase 2
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive LymphomaPfizerPhase 2

See all PF-06463922 clinical trials

Clinical Trial Summary for PF-06463922

Top disease conditions for PF-06463922
Top clinical trial sponsors for PF-06463922

See all PF-06463922 clinical trials

US Patents for PF-06463922

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06463922   Start Trial Substituted macrocycles useful as kinases inhibitors and methods of use thereof Teligene Ltd. (Suzhou, CN)   Start Trial
PF-06463922   Start Trial Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
PF-06463922   Start Trial CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
PF-06463922   Start Trial Macrocyclic derivatives for the treatment of diseases Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06463922

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06463922 China 107207528 2034-08-20   Start Trial
PF-06463922 European Patent Office 3183256 2034-08-20   Start Trial
PF-06463922 Japan 2017525716 2034-08-20   Start Trial
PF-06463922 Argentina 102035 2034-07-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Colorcon
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.